Novartis shares Zolgensma long-term information demonstrating sustained sturdiness as much as 7.5 years post-dosing; 100% achievement of all assessed milestones in youngsters
Youngsters in LT-001 handled after SMA symptom onset maintained or achieved extra milestones as much as 7.5 years put up one-time intravenous infusionAll youngsters (100%)...